ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 25 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $16.52 million which beat the analyst consensus estimate of $16.02 million by 3.13 percent. This is a 41.19K percent increase over sales of $40.00 thousand the same period last year.